Octapharma Accepting Applications for Research Grants Through March 31

LACHEN, Switzerland and HOBOKEN, N.J., Feb. 4 /PRNewswire/ -- Octapharma USA will accept applications until March 31 for the Octapharma 25th Anniversary Grants Program, which supports clinical or pre-clinical research focused on human protein therapies in coagulation disorders, immunotherapy, intensive care and emergency medicine. Applications will be reviewed in April.

Octapharma AG, one of the largest plasma products manufacturers in the world, launched the grants program last year in celebration of the biopharmaceutical company's 25th anniversary. The company's first ever grants program is only available to researchers based in the United States and is administered by Octapharma USA, the Swiss company's rapidly-growing U.S. subsidiary.

"The grants program has been very well-received and we expect to be announcing our first recipient shortly," said Octapharma USA President Flemming Nielsen. "The U.S. market is very important to Octapharma and the grants program is just one way that we demonstrate our commitment. Our vision of providing patients with the safest, highest quality products available is stronger than ever."

Grant applications are accepted online only at www.octapharmagrants.com.  All grant requests will be evaluated by the Octapharma Grants Committee in April and grant recipients will be announced shortly afterward. Please visit www.octapharmagrants.com for a complete description of the grants program, including the application and review process.

About the Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma is one of the largest plasma products manufacturers in the world and has been committed to patient care and medical innovation for over 25 years. Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam® (immune globulin intravenous [human] 5%), is used to treat disorders of the immune system, and Octapharma's albumin (Human) is indicated for the restoration and maintenance of circulating blood volume. Octapharma's wilate® was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of von Willebrand disease (VWD) and granted orphan drug exclusivity. Octapharma employs over 3,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, N.J. Octapharma operates two state-of-the-art production sites licensed by the FDA, providing a high level of production flexibility. For more information, please visit www.octapharma.com.

SOURCE Octapharma USA

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED